Skip to main content

Advertisement

SpringerLink
Log in

Guillain–Barré Syndrome Associated with COVID-19

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

We present two clinical cases of Guillain–Barré syndrome associated with COVID-19 coronavirus infection. The clinical picture and neurological status of the patients, investigation data, and the characteristicsof the therapy prescribed are described in detail. The question of the tropism of the SARS-CoV-2 virus in relation to human nervous tissue and possible pathways of its effects on the peripheral nervous system are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Raevskaia, A. I., Shevchenko, P. P., and S. M. Karpov, “Current methods in the diagnosis and treatment of Guillain–Barré syndrome,” Vestn. Molod. Uchen., 8, No. 4, 136–141 (2019), https://www.elibrary.ru/item.asp?id=42748999, acc. Feb. 13, 2022.

  2. Federal Clinical Guidelines for the Provision of Healthcare to Patients with Guillain–Barré Syndrome (online resource), https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/_kr_sgb.pdf, acc. Feb. 13, 2022.

  3. Suponeva, N. A., Piradov, M. A., and Gnedovskaya, E. V., “Guillain–Barré syndrome in cities of the Russian Federation: epidemiology, diagnostic and therapeutic capabilities of reginal clinics,” Zdravookhr. Ross. Feder., 1, 19–25 (2013), https://cyberleninka.ru/article/n/sindrom-giyena-barre-v-gorodah-rossiyskoy-federatsii-epidemiologiya-diagnosticheskie-i-terapevticheskie-vozmozhnosti-regionalnyh,acc. Feb. 13, 2022.

  4. Bondar’, S. A., Maslyanskii, A. L., Smirnova, A. Yu., et al., “Guillain–Barré syndrome and COVID-19: clinical cases,” Ross. Med. Zh., 5, 60–64 (2021), https://www.rmj.ru/articles/nevrologiya/Sindrom_Giyena__Barre_i_COVID-19_klinicheskie_nablyudeniya, acc. Feb. 13, 2022.

  5. Chaikovskaya, A. D., Ivanova, A. D., Ternovykh, I. K., et al., “Guillain–Barré syndrome on the background of COVID-19 infection,” Sovrem. Prob. Nauki Obraz., 4, 23–28 (2020), https://doi.org/10.17513/spno.29950.

  6. Shakaryan, A. K., Pylaeva, S. K., Perekopskaya, N. E., et al., “Guillain–Barré syndrome affecting mainly the cranial nerves as a complication of COVID-19,” Zh. Nevrol. Psikhiatr., 121, No. 9, 100–103 (2021), https://doi.org/10.17116/jnevro2021121091100.

  7. Shirshova, E. V., Knaub, V. V., and Baklaushev, V. P., “Clinical cases of Guillain–Barré syndrome associated with COVID-19,” Klinich. Prakt., 12, No. 2, 110–118 (2021), https://doi.org/10.17816/clinpract72264.

  8. Guillain–Barré Syndrome. Clinical Guidelines of the Ministry of Health of the Russian Federation (online resource), https://neuromuscular.ru/wp-content/uploads/2020/10/KR-SGB-2020-FINAL.pdf, acc. Feb. 13, 2022.

  9. Fokke, B., van den Berg, B., Drenthen J., et al., “Diagnosis of Guillain–Barré syndrome and validation of Brighton criteria,” Brain, 137, No. 1, 33–43 (2014), https://doi.org/10.1093/brain/awt285.

    Article  PubMed  Google Scholar 

  10. Abu-Rumeileh, S. Abdelhak, A., Foschi, M., et al., “Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases,” J. Neurol., 268, No. 4, 1133–1170 (2021), https://doi.org/10.1007/s00415-020-10124-x.

    Article  CAS  PubMed  Google Scholar 

  11. Garg, R. K., “Spectrum of neurological manifestations in COVID-19: A Review,” Neurol. India, 68, No. 3, 560–572 (2020), https://doi.org/10.4103/0028-3886.289000.

    Article  PubMed  Google Scholar 

  12. Gupta, A., Paliwal, V. K., and Garg, R. K., “Is COVID-19-related Guillain–Barré syndrome different?” Brain Behav. Immun., 87, 177–178 (2020), https://doi.org/10.1016/j.bbi.2020.05.051.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Shoraka, S., Ferreira, M. L. B., Mohebbi, S. R., and Ghaemi, A., “SARS-CoV-2 infection and Guillain–Barré syndrome: A review on potential pathogenic mechanisms,” Front. Immunol., 12, 674922 (2021), https://doi.org/10.3389/fimmu.2021.674922.

  14. Belopasov, V. V., Yashu, Ya., Samoilova, E. M. and Baklaushev, V. P., “Nervous system lesions in COVID-19,” Klinich. Prakt., 11, No. 2, 60–80 (2020), https://doi.org/10.17816/clinpract34851.

  15. Baig, A. M., Khaleeq, A., Ali, U., and Syeda, H., “Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms,” ACS Chem. Neurosci., 11, No. 7, 995–998 (2020), https://doi.org/10.1021/acschemneuro.0c00122.

    Article  CAS  PubMed  Google Scholar 

  16. Martynov, M. Yu., Bogolepova, A. N., and Yasamanova, A. N., “Endothelial dysfunction in COVID-19 and cognitive impairments,” Zh. Nevrol. Psikhiatr., 121, No. 6, 93–99 (2021), https://doi.org/10.17116/jnevro202112106193.

  17. Temporary Guidelines. Prophylaxis, Diagnosis, and Treatment of the New Coronavirus Infection(COVID-19), Version 15, Feb. 22, 2022 (online resource), Ministry of Health of the Russian Federation (2022), https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/BMP_COVID-19_V15.pdf, acc. March 22, 2022.

  18. Jarius, S., Pache, F. Körtvelyessy, P., et al., “Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients,” J. Neuroinflammation, 19, No. 1, 19 (2022), https://doi.org/10.1186/s12974-021-02339-0.

  19. Arnaud, S., Budowski, C., Ng Wing Tin, S, and Degos, B., “Post SARSCoV-2 Guillain–Barré syndrome,” Clin. Neurophysiol., 131, No. 7, 1652–1654 (2020), https://doi.org/10.1016/j.clinph.2020.05.003.

  20. Finsterer, J. and Almas, T., “Guillain–Barré syndrome is immunogenic in SARS-CoV-2 infected,” J. Med. Virol., 94, No. 1, 22–23 (2022), https://doi.org/10.1002/jmv.27314.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. City Clinical Polyclinic No. 6, Stavropol, Russia

    A. A. Bogdanova

  2. Stavropol State Medical University, Russian Ministry of Health, Stavropol, Russia

    E. S. Kravtsunova, A. I. Raevskaia, A. S. Karpov, R. N. Gadaborshev, A. I. Dzutsev, I. A. Vyshlova & S. M. Karpov

Authors
  1. A. A. Bogdanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. S. Kravtsunova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. I. Raevskaia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. S. Karpov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. N. Gadaborshev
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. I. Dzutsev
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. A. Vyshlova
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. M. Karpov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. S. Kravtsunova.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 122, No. 9, pp. 132–136, September, 2022.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bogdanova, A.A., Kravtsunova, E.S., Raevskaia, A.I. et al. Guillain–Barré Syndrome Associated with COVID-19. Neurosci Behav Physi 53, 763–766 (2023). https://doi.org/10.1007/s11055-023-01466-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-023-01466-w

Keywords

Search

Navigation